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Abstract. Collapsing glomerulopathy
(CG) is a severe form of glomerulopathy
which results in nephrotic syndrome and often ensues in rapid progression to end-stage
kidney disease (ESKD). Although most
commonly a result of HIV infection, other
conditions such as parvovirus B19 (PB19)
infection have been associated with CG. We
present a case of an 18-year-old male with
CG associated with PB19 infection who was
heterozygous for APOL1 G1 and G2 genetic
variants. In an attempt to treat, he was started
on intravenous immunoglobulin (IVIg), however rapidly progressed to ESKD. During
workup for a living donor kidney transplant
he was found to have persistent low-grade
PB19 viremia. Despite having no major immunodeficiency and given subsequent courses of IVIg, viremia continued to persist. In a
final attempt to eradicate the PB19 we began
treatment with cidofovir, an antiviral agent
with in vitro efficacy against PB19. Subsequent to initiation of cidofovir, PB19 viremia
slowly cleared after which he received a living unrelated kidney transplant. The patient
had an early cellular rejection treated with
rabbit antithymocyte globulin after which he
recovered kidney function without signs of
recurrent CG. Our case report suggests efficacy of IVIg and cidofovir for persistent
PB19 infection in ESKD to allow subsequent
transplantation, while minimizing the risk of
recurrent CG.

Introduction
Collapsing glomerulopathy (CG) is a
rapidly progressing glomerular disease that
often is resistant to treatment. Classically,
CG occurs in association with human immunodeficiency virus (HIV) infection. HIVinduced CG is thought to be triggered by in-

fection of kidney epithelial cells by HIV in
genetically susceptible hosts [1, 2]. Genetic
susceptibility has been suggested by the
strong association with African ancestry and,
more specifically, single nucleotide polymorphisms in the APOL1 gene (G1/G1, G1/
G2, or G2/G2) [2]. Parvovirus B19 (PB19)
is a virus that has also been associated with
CG [3]. Infection has been shown to coincide with the onset of kidney disease, and
PB19 has been found in epithelial cells of
patients with CG [4]. The exact mechanism
by which PB19 infection leads to CG, however, is unknown. Although our understanding of CG has expanded, treatment options
remain poor. Treatment of HIV-induced CG
revolves around antiretroviral therapy, while
in idiopathic CG, steroids and immunosuppressive agents are often used to no avail. As
studies suggest treatment with antiretroviral
therapy improves renal survival, it is intuitive that treatment of PB19-associated CG
may also improve renal outcome [5].
While data is limited to case reports and
case series, in PB19-induced CG, kidney
transplantation can be performed, however
recurrent disease may occur. Whether recurrence depends upon PB19 status of the recipient, genetic background of the donor, or
is independent of these factors is unknown.
We present a patient diagnosed with PB19associated CG who rapidly progressed to
end-stage kidney disease (ESKD) despite
treatment with intravenous immunoglobulin (IVIg). Further evaluation was negative
for significant immunodeficiency but positive for APOL1 genetic variants G1 and G2.
Subsequently, he was treated with cidofo-
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He began evaluation for kidney transplantation, and a non-related African American living donor was identified.

Figure 1. The glomerulus reveals features of collapsing glomerulopathy, with epithelial cell proliferation and collapse of underlying capillary walls.
Tubules reveal flattening of the epithelium, distension of lumens, and focal intraluminal accumulation
of cellular debris (periodic acid-Schiff stain, × 200).

vir which eventually resulted in PB19 viral
clearance and a successful live donor kidney
transplant. Our case suggests efficacy of
IVIg and cidofovir for persistent PB19 infection in ESKD to allow subsequent transplantation, while minimizing the risk of recurrent
CG.

Case report
The patient is an 18-year-old African
American male hospitalized for elevated serum creatinine (2.74 mg/dL) and nephrotic
syndrome. Serological evaluation revealed
negative anti-nuclear antibody, anti-dsDNA,
c-ANCA, p-ANCA, hepatitis B and C antibodies, HIV, and anti-glomerular basement
membrane antibody. Complement C3 and
C4 levels were normal, and serum free light
chain ratio was not elevated or suppressed.
Kidney biopsy revealed morphological findings of CG (Figure 1). PB19 viral load was
elevated at 96,600 IU/mL. There were no recent respiratory infections or history of recurrent infections as a child. He was given 2 g/
kg IVIg in an attempt to treat the PB19. His
initial viral load increased to 107,000 IU/mL
but then subsequently decreased to 800 IU/
mL by November 2017. Despite the reduction in PB19 titer, his kidney function rapidly
decreased and he was initiated on dialysis.

In an attempt to eradicate the PB19 infection before transplantation he was given
2 more courses of 2 g/kg IVIg over the next
4 months. His viral load remained positive
at low levels. Further immunologic evaluation was negative except for low mannanbinding lectin (< 70 ng/mL, normal > 100).
PB19 IgG was positive, but PB19 IgM was
negative. Genetic testing found the patient to
be heterozygous for APOL1 G1/G2 alleles.
A second attempt to eradicate the PB19 viremia began with cidofovir treatment based
on published in vitro efficacy [6]. The patient
received cidofovir 0.5 mg/kg every 2 weeks
as suggested by a pharmacologic study of cidofovir in patients with kidney disease [7].
He received a total of 7 doses of cidofovir
before PB19 viral load became negative. As
his donor was available for a limited window
of time, it was decided to proceed with living donor transplantation after administering
the 8th dose of cidofovir. Five days after the
8th dose of cidofovir, he received a living unrelated kidney transplant. Induction immunosuppression included methylprednisolone
500 mg at the time of surgery and basiliximab on post-operative day (POD) 0 and 4.
He was maintained on tacrolimus, mycophenolate mofetil, and corticosteroids were tapered to prednisone 5 mg daily over 5 days.
Due to the intense immunosuppression associated with induction, the patient was given a
9th dose of cidofovir on post-operative day 2
(7 days from the previous dose of cidofovir).
Creatinine immediately decreased following transplant but then increased by POD 4.
PB19 viral load was repeated and found to
be positive at 1,100 IU/mL. Subsequently,
a kidney biopsy was performed on POD 5
which revealed a Banff grade 2a rejection.
As there was no evidence of CG on biopsy
but clear vascular rejection, the clinical team
decided that the risk of worsening PB19 viral
replication by aggressive treatment of rejection was outweighed by the clear negative
impact of ongoing rejection. Therefore the
patient was treated with 10 mg/kg of rabbit
antithymocyte globulin and steroid bolus.
Kidney function improved, and a repeat kidney biopsy 2 weeks after treatment revealed
mild acute tubular injury and no evidence of
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ney transplantation. We offer a novel in-vivo
treatment option for persistent PB19 infection and report on post-transplant outcome.

Figure 2. Kinetics of PB19 viremia from detection
to 6 weeks after transplantation (A) and a magnified view of viral loads of PB19 (notice the Y axis
difference) from the initiation of the second course
of intravenous immunoglobulin (B). IVIg = intravenous immunoglobulin 500 mg/kg (gray dot); CDV =
cidofovir 0.5 mg/kg (blue dot); dotted line = day of
transplantation.

CG or podocyte effacement. Repeat PB19
viral load 1 month later revealed a decrease
in PCR to the lower limit of laboratory testing < 199 IU/mL. The kinetics of PB19 viremia from the time of diagnosis to 6 weeks
after transplantation is seen in Figure 2.
Other viruses including cytomegalovirus
and polyoma (BK) virus were not detected.
Ten months post transplant his creatinine is
2 mg/dL, and there is no proteinuria. PB19
has remained detected but < 199 IU/mL up
to 6 months post transplant after which it has
no longer been tested.

Discussion
An increasing body of literature suggests
an association between PB19 infection and
CG. In patients with persistent parvoviral infection that progress to ESKD, not much is
known about the risk of recurrence after kid-

Several studies have found high prevalence of PB19 DNA in patients with CG [4].
Whether due to direct infection of epithelial
cells or indirect effects of viral infection is
unclear. In a study by Moudgil et al. [4],
PB19 DNA was detected in 78% of kidney
biopsies from patients with CG. Viral genome was detected in the renal epithelial
cells suggesting a direct effect of viral infection on cell hyperplasia. A similar study
found PB19 DNA in 90% of patients with
CG [8]. Since the discovery of APOL1 it is
now clear that individuals with at-risk genetic variants (G1/G1, G1/G2, or G2/G2) carry
a much higher risk of CG when also infected
by HIV [2]. Similarly, it is likely that there
is an interplay between PB19 and APOL1
which leads to CG. A report by Besse et al.
[9], details the development of CG over 3
biopsies in a patients with APOL1 high-risk
alleles and acute PB19 infection. Our patient
was a healthy African American male who
developed CG in a similar manner, in the setting of high-titer PB19 viremia.
Treatment of CG can be difficult. Before
the advent of HIV antiretroviral therapy, CG
was the most common glomerulopathy in
HIV-positive individuals. The advent of antiretroviral therapy has lowered the incidence
of CG suggesting a role of treatment by viral control. If we hypothesize that a similar
process exists between PB19 and APOL1,
it is reasonable to believe that treatment of
PVB19 may improve kidney outcomes in
PB19-associated CG. Unfortunately, treatment options for PB19 are limited. IVIg
has been used after kidney transplantation
to treat PB19-induced aplastic anemia [10].
However, few authors have reported on the
use of IVIg for chronic PB19 infections in
patients without immunodeficiency. In one
report, PB19-associated vasculitis and viremia improved after IVIg [11]. Both cidofovir and brincidofovir have been found to
inhibit PB19 replication in vitro. Despite
the inhibitory properties of cidofovir on
PB19 replication in vitro, to our knowledge
it has never been used in vivo and is generally contraindicated in kidney disease [6].
Brincidofovir, a lipid conjugate of cidofovir,
seems to be safe in chronic kidney disease
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(CKD) however is not FDA approved [12].
Although avoided in CKD, pharmacokinetics of cidofovir have been studied in hemodialysis patients [7]. Based on this study, we
dosed our patient with cidofovir 0.5 mg/kg
every 2 weeks. Although viremia was low, it
began to increase after IVIg was completed
but cleared after 7 doses of cidofovir. He was
given an 8th dose of cidofovir in preparation of transplant, then given a 9th dose post
transplantation during the period of intense
immunosuppression. Our patient did not exhibit any side effects of treatment. This is an
important finding as there are no published
reports on the successful use of cidofovir in
vivo to treat PB19 viremia and limited data
on its use in ESKD. However, the decision
to start cidofovir cannot be taken lightly as
cidofovir has significant nephrotoxicity and
may hasten ESKD in patients with CKD.
Our patient had a transient increase of PB19
viremia post transplant which quickly returned to the lower limit of laboratory testing
despite receiving antithymocyte globulin for
rejection.
To our knowledge there is only one study
which helps understand the risk of recurrent
PVB19-induced CG after transplantation.
Barsoum et al. [13] reported on a patient
who developed anemia and nephrotic proteinuria which culminated in graft failure
of her second kidney transplant. After being
transplanted for the third time, the anemia
and proteinuria reoccurred and biopsy revealed CG. The patient was found to have
PVB19 viremia and lost the graft. Retrospective analysis of stored blood from the second
transplant revealed PVB19 viremia to also
have been present. Finally, after withdrawing all immunosuppression and clearing
PVB19 viremia, she received a fourth transplant without recurrence of anemia or CG,
suggesting PVB19 should be cleared before
retransplantation. However recent studies
on de novo CG suggest that it is the donors
APOL1 genotype which actually dictates the
risk for CG [14, 15]. In one such study, 5
transplanted kidneys that went on to develop
CG in different recipients were all found to
carry two APOL1 risk alleles. Four of the 5
patients that received these kidneys had viremia (CMV and BK) preceding the development of CG; suggesting a “second hit” may
trigger CG in a donor organ which exhibits

high-risk alleles [14]. We could have sent
our donor’s APOL1 genotype, however it
was not performed as it was not a part of our
donor workup process and PB19 treatment
was successful.
In conclusion, PB19 infection in patients
with high-risk APOL1 alleles are at risk of
developing CG. In such patients with chronic
viremia, there are no proven treatment options. Our case suggests IVIg and cidofovir
may be helpful in treating chronic PB19 viremia. Whether earlier eradication of viremia can alter the course of CG is unknown.
Furthermore, in such patients where viremia
resolves, kidney transplantation appears to
be a safe option. Whether this is a result of
control of viremia, thereby avoiding a “second hit,” or the donors APOL1 genotype, or
possibly both requires further study.
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